NAMSW
NewAmsterdam Pharma Company N.V.
—
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
None
$14.49
+$1.84 (+17.02%)
Price History
52-Week Range
Sign in to add NAMSW to a watchlist or set price alerts.
Fundamentals
| Market Cap | - |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | - |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | 2.10% |
| ROE | -29.49% |
| Debt/Equity | 0.00 |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 18.3 |
| Beta | 0.08 |
| SMA 20 | $20.81 |
| SMA 40 | $20.41 |
| 52-Week High | $30.45 |
| 52-Week Low | $10.23 |
| 50-Day Avg | $21.38 |
| 200-Day Avg | $22.97 |
| Avg Volume | 704 |
| Volume | 6 |
Performance Analysis
NEUTRALNAMSW presents a mixed picture with both positive and negative indicators.
~
Trading at 21% of its 52-week range.
+
RSI at 18.3 signals oversold conditions — a bounce may be ahead.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
~
Modest revenue growth of 2.1% year-over-year.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Aug 01, 2026 04:12 UTC
Back to Screener Export Report